+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07565506

Evaluating Safety and Antimicrobial Effects of Twice Daily Nu-3 Gel at 2%, 5%, and 10% Doses for Mildly Infected Diabetic Foot Ulcers in Adults

Led by Lakewood-Amedex Inc · Updated on 2026-09-02

24

Participants Needed

6

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the drug Nu-3 to treat mildly infected diabetic foot ulcers in adults with Type 1 or Type 2 diabetes. The study aims to find out if Nu-3 reduces bacteria or viruses in the ulcers and cures infections at three different dose levels, while also assessing the safety of the drug over a short period. This Phase 2a randomized, single-blind trial compares the antimicrobial effects of three concentrations of Nu-3 gel applied topically. Participants will be assigned to one of three groups receiving either 2%, 5%, or 10% Nu-3 gel applied twice daily to the infected ulcer for 14 days. Alongside the study drug, all participants will receive standard wound care. The study includes screening, treatment, and follow-up phases, with enrollment and treatment starting quickly after confirming eligibility and screening tests, including lab work and foot X-rays. During the trial, participants will attend multiple clinic visits for assessments including wound inspections, microbiological cultures via biopsies and swabs, and safety evaluations up to 4 weeks after enrollment. Researchers will monitor infection signs closely, record adverse events, and measure outcomes such as infection reduction and treatment success. Participants will also keep diaries of symptoms and treatment use, helping assess the drugs tolerability and safety throughout the study.

CONDITIONS

Brief Title

Phase 2a Dose Finding Study of Nu-3 Gel in Subjects With Mild iDFU

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here